IMMUNIC, INC.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
IMUX$8.04+1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(52,293) | $(50,964) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 86 | 57 |
| Unrealized foreign currency gain | — | (147) |
| Stock-based compensation | 3,941 | 4,632 |
| Non-cash lease expense | 108 | 342 |
| Change in fair value of tranche rights | — | 4,796 |
| Fees expensed as part of January 2024 Financing | — | 1,690 |
| Changes in operating assets and liabilities: | ||
| Other current assets and prepaid expenses | (429) | 375 |
| Accounts payable | (896) | 2,977 |
| Accrued expenses | 3,447 | (4,420) |
| Other liabilities | (231) | 4 |
| Operating lease liability | (118) | (350) |
| Net cash used in operating activities | (46,385) | (41,008) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (83) | (211) |
| Net cash used in investing activities | (83) | (211) |
| Cash flows from financing activities: | ||
| Proceeds from public offering of common stock through At The Market Sales Agreement, net | — | 191 |
| Proceeds from January 2024 Financing, net of issuance costs | — | 74,273 |
| Proceeds from shares issued in connection with the Company's employee stock purchase plan | 123 | — |
| Proceeds from May 2025 Offering, net of issuance costs | 60,661 | — |
| Proceeds from April 2025 Offering, net of issuance costs | 4,734 | — |
| Net cash provided by financing activities | 65,518 | 74,464 |
| Effect of exchange rate changes on cash and cash equivalents | 592 | (221) |
| Net change in cash and cash equivalents | 19,642 | 33,024 |
| Cash and cash equivalents, beginning of period | 35,668 | 46,674 |
| Cash and cash equivalents, end of period | $55,310 | $79,698 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Conversion of tranche rights liability to equity upon increase in authorized shares | $— | $28,396 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.